|
Sign In to gain access to subscriptions and/or personal tools.
|
Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis
D G Wahl
Service de Medecine H. Nancy University Hospital, Nancy, France
F Guillemin
Ecole de santé publique, Faculté de Medicine, Vandoeuvre-les-Nancy, Nancy, France
E de Maistre
Laboratoire d'hémostase, Nancy University Hospital, Nancy, France
C Perret-Guillaume
Service de Medecine H. Nancy University Hospital, Nancy, France
T Lecompte
Laboratoire d'hémostase, Nancy University Hospital, Nancy, France
G Thibaut
Service de Medecine H. Nancy University Hospital, Nancy, France
Patients with systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) are at a greater risk for venous thromboembolism (VTE) than SLE patients without these antibodies. For patients without SLE there is a controversy about the risk associated with these antibodies and about their prognostic significance. We reviewed the degree of evidence and describe the odds ratio for VTE associated with aPL, namely the lupus anticoagulant (LA) and anticardiolipin antibodies (aCL), in patients without SLE. The study was a meta-analysis of seven observational studies of risk for antiphospholipid associated venous thromboembolism (VTE), excluding SLE patients. The strategies to identify published research included a computerized literature search and the review of citations in primarily relevant articles for the period 1983 to 1997. A summary of study characteristics and a critical appraisal of study quality were done. Summary odds ratios were obtained conducted using a random and a fixed effects-model. The overall odds ratio for aCL associated VTE obtained by fixed-effects model was 1.56 (95% CI, 1.10—2.24) and 1.64 (95% CI, 0.93—2.89) by random-effects model. The heterogeneity of these results appeared to be due in part to the detection limit of the aCL assay: the odds ratio was 3.21 (95% CI, 1.11—9.28) with both models when high titres only were considered. The overall odds ratio for LA associated VTE was 11.1 (95% CI, 3.81—32.3). In conclusion meta-analysis of the risk for antiphospholipid associated thrombosis demonstrated a higher risk in patients with the LA than in other patients. This risk was also higher than in patients with aCL even when high titres only were considered.
Key Words: anticardiolipin antibodies • lupus anticoagulant • antiphospholipid antibodies • Hughes' syndrome • venous thrombosis
Lupus, Vol. 7, No. 1,
15-22 (1998)
DOI: 10.1191/096120398678919688
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Hasegawa, M. Caleiro, R Fuller, and J. Carvalho
The frequency of anti-{beta}2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease
Lupus,
June 1, 2009;
18(7):
618 - 621.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. K. Farmer-Boatwright and R. A.S. Roubey
Venous Thrombosis in the Antiphospholipid Syndrome
Arterioscler Thromb Vasc Biol,
March 1, 2009;
29(3):
321 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Giannakopoulos, F. Passam, Y. Ioannou, and S. A. Krilis
How we diagnose the antiphospholipid syndrome
Blood,
January 29, 2009;
113(5):
985 - 994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Moore, S. Rangarajan, and G. F. Savidge
The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2008;
14(3):
332 - 337.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M L Bertolaccini and M A Khamashta
Laboratory diagnosis and management challenges in the antiphospholipid syndrome
Lupus,
March 1, 2006;
15(3):
172 - 178.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Lim, M. A. Crowther, and J. W. Eikelboom
Management of Antiphospholipid Antibody Syndrome: A Systematic Review
JAMA,
March 1, 2006;
295(9):
1050 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Ortel
Thrombosis and the Antiphospholipid Syndrome
Hematology,
January 1, 2005;
2005(1):
462 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Saadoun, D Cazals-Hatem, M-H Denninger, L Boudaoud, B-N Pham, V Mallet, B Condat, J Briere, and D Valla
Association of idiopathic hepatic sinusoidal dilatation with the immunological features of the antiphospholipid syndrome
Gut,
October 1, 2004;
53(10):
1516 - 1519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Ozturk, I. C. Haznedaroglu, M. Turgut, and H. Goker
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2004;
10(2):
89 - 126.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Proven, R. P. Bartlett, K. G. Moder, A. Chang-Miller, L. K. Cardel, J. A. Heit, H. A. Homburger, T. M. Petterson, T. J. H. Christianson, and W. L. Nichols
Clinical Importance of Positive Test Results for Lupus Anticoagulant and Anticardiolipin Antibodies
Mayo Clin. Proc.,
April 1, 2004;
79(4):
467 - 475.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit
Thrombophilia and New Anticoagulant Drugs
Hematology,
January 1, 2004;
2004(1):
424 - 438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tripodi, A. Biasiolo, V. Chantarangkul, and V. Pengo
Lupus Anticoagulant (LA) Testing: Performance of Clinical Laboratories Assessed by a National Survey Using Lyophilized Affinity-purified Immunoglobulin with LA Activity
Clin. Chem.,
October 1, 2003;
49(10):
1608 - 1614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Galli, D. Luciani, G. Bertolini, and T. Barbui
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
Blood,
March 1, 2003;
101(5):
1827 - 1832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R Deitcher and M. P. Gomes
Hypercoagulable state testing and malignancy screening following venous thromboembolic events
Vascular Medicine,
February 1, 2003;
8(1):
33 - 46.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Jankowski, I. Vreys, C. Wittevrongel, D. Boon, J. Vermylen, Marc. F. Hoylaerts, and J. Arnout
Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster
Blood,
January 1, 2003;
101(1):
157 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Yee, S. J. Schuster, and G. R. Lichtenstein
Ischemic Colitis Associated with Anti-{beta}2 Glycoprotein-I Antibody
Ann Intern Med,
August 20, 2002;
137(4):
299 - 299.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. Macik, J. H. Rand, and B. A. Konkle
Thrombophilia: What's a Practitioner to Do?
Hematology,
January 1, 2001;
2001(1):
322 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Detkova, A Gil-Aguado, P Lavilla, M V Cuesta, G Fontaan, and D Pascual-Salcedo
Do antibodies to {beta}2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?
Lupus,
July 1, 1999;
8(6):
430 - 438.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Brey and A. Escalante
Review : Neurological manifestations of antiphospholipid antibody syndrome
Lupus,
January 1, 1998;
7(2_suppl):
S67 - S74.
[Abstract]
[PDF]
|
|
|
|
|
